Sterically stabilized liposome therapeutics

Abstract Biotechnology, based on the concept of natural macromolecules as therapeutic agents while successful has been thwarted by a need for in vivo delivery. Sterically stabilized liposomes, ones modified at the surface with hydrophilic polymers (PEG), have proven to reduce in vivo recognition and phagocytic uptake, resulting in prolonged circulation and localization in tumors as well as other sites of pathology. This has restored their potential as a widely useful delivery system but also has created new challenges: the need to keep the agent associated with the liposome during circulation and distribution followed by control of its release for activity. Several specific drug formulations have been developed which are described along with some of the important parameters for their consideration in order to be considered for other agents. Finally, the value and issues surrounding future expansion are discussed: targeting and cell delivery for gene therapy.

[1]  Y. Barenholz,et al.  In vitro tests to predict in vivo performance of liposomal dosage forms. , 1993, Chemistry and physics of lipids.

[2]  J. Cohen,et al.  Sterically stabilized liposomes: physical and biological properties. , 1994, Journal of drug targeting.

[3]  A A Bogdanov,et al.  Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. , 1994, Biochimica et biophysica acta.

[4]  G Blume,et al.  Molecular mechanism of the lipid vesicle longevity in vivo. , 1993, Biochimica et biophysica acta.

[5]  F. Martin,et al.  Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.

[6]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[7]  R. Langer,et al.  Biodegradable polymers as drug delivery systems , 1990 .

[8]  R. Perez-soler,et al.  Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells. , 1994, Anticancer research.

[9]  Y. Barenholz,et al.  Clinical studies of liposome-encapsulated doxorubicin. , 1994, Acta oncologica.

[10]  A. Domb.  Polymeric site-specific pharmacotherapy , 1994 .

[11]  H. Kikuchi,et al.  Phosphatidyl polyglycerols prolong liposome circulation in vivo , 1994 .

[12]  M. Woodle,et al.  Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.

[13]  T. Allen,et al.  Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. , 1992, Cancer research.

[14]  A. Coldman,et al.  Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. , 1993, Journal of pharmaceutical sciences.

[15]  G. Storm,et al.  In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. , 1992, Cancer research.

[16]  M. Papisov,et al.  Why do Polyethylene Glycol-Coated Liposomes Circulate So Long?: Molecular Mechanism of Liposome Steric Protection with Polyethylene Glycol: Role of Polymer Chain Flexibility , 1994 .

[17]  P. Stauffer,et al.  Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. , 1994, Cancer research.

[18]  F. Martin,et al.  Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid , 1992, International journal of cancer.

[19]  Y. Barenholz,et al.  Gelation of liposome interior A novel method for drug encapsulation , 1992, FEBS letters.

[20]  J H Senior,et al.  Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.

[21]  J. M. Harris,et al.  Poly(Ethylene Glycol) Chemistry Biotechnical and Biomedical Applications , 1992 .

[22]  D. Lasič,et al.  Liposomes: From Physics to Applications , 1993 .

[23]  D. Lasič,et al.  Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes , 1992, International journal of cancer.

[24]  G. Gregoriadis.  Liposomes as drug carriers : recent trends and progress , 1988 .

[25]  P. Working,et al.  Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts , 1994, Cancer.

[26]  M. Woodle.  Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. , 1993, Chemistry and physics of lipids.

[27]  I. Ahmad,et al.  Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. , 1993, Cancer research.

[28]  M. Woodle,et al.  67Gallium-labeled liposomes with prolonged circulation: preparation and potential as nuclear imaging agents. , 1993, Nuclear medicine and biology.

[29]  M. Bally,et al.  Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. , 1990, Cancer research.

[30]  A. Gabizon,et al.  Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.

[31]  V. Torchilin,et al.  Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.

[32]  R. Perez-soler,et al.  Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use. , 1994, Journal of microencapsulation.

[33]  G. Storm,et al.  Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.

[34]  Beverly A. Teicher,et al.  Drug resistance in oncology , 1993 .

[35]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[36]  R. Perez-soler,et al.  Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. , 1994, Cancer research.

[37]  D. Tzemach,et al.  Preclinical Studies with Doxorubicin Encapsulated in Polyethyleneglycol-Coated Liposomes , 1993 .

[38]  V. Torchilin,et al.  Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  M. C. Lima,et al.  Liposomes, viruses and membrane fusion , 1994 .

[40]  Rakesh K. Jain.  Physiological resistance to the treatment of solid tumors , 1993 .

[41]  V. Vlassov,et al.  Transport of oligonucleotides across natural and model membranes. , 1994, Biochimica et biophysica acta.

[42]  M. Bally,et al.  Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. , 1994, Journal of pharmaceutical sciences.

[43]  D. Coulter,et al.  Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. , 1992, Cancer research.

[44]  S. Balasubramanian,et al.  Taxol-lipid interactions: taxol-dependent effects on the physical properties of model membranes. , 1994, Biochemistry.

[45]  I. Ahmad,et al.  Antibody-Mediated Targeting of Long-Circulating (StealthR) Liposomes , 1994 .

[46]  F. Martin,et al.  Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. , 1993, The American journal of pathology.

[47]  P. Vierling,et al.  Fluorinated phosphatidylcholine-based liposomes: H+/Na+ permeability, active doxorubicin encapsulation and stability, in human serum. , 1994, Biochimica et biophysica acta.

[48]  I. Fichtner,et al.  Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. , 1993, Journal of microencapsulation.

[49]  T. Yotsuyanagi,et al.  Chemotherapy Targeting Regional Lymph Nodes by Gastric Submucosal Injection of Liposomal Adriamycin in Patients with Gastric Carcinoma , 1994, Japanese journal of cancer research : Gann.

[50]  F. Nestle,et al.  Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. , 1994, The Journal of investigative dermatology.

[51]  M. Ostro.  Liposomes : from biophysics to therapeutics , 1987 .

[52]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[53]  I. Kellaway,et al.  Specific accumulation of technetium-99m radiolabelled, negative liposomes in the inflamed paws of rats with adjuvant induced arthritis: effect of liposome size. , 1989, Annals of the rheumatic diseases.

[54]  V. Torchilin,et al.  Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. , 1994, Biochimica et biophysica acta.

[55]  Robert Gurny,et al.  Drug-loaded nanoparticles : preparation methods and drug targeting issues , 1993 .

[56]  D. Leckband,et al.  Modulation of interaction forces between bilayers exposing short-chained ethylene oxide headgroups. , 1994, Biophysical journal.

[57]  T. V. van Berkel,et al.  Properties of incorporation, redistribution, and integrity of porphyrin-low-density lipoprotein complexes. , 1993, Biochemistry.

[58]  S. Zalipsky.  Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. , 1993, Bioconjugate chemistry.

[59]  M. Dewhirst,et al.  Polymer-Grafted Liposomes: Physical Basis for the “Stealth” Property , 1992 .

[60]  F. Martin,et al.  Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. , 1993, Cancer research.

[61]  G. Storm,et al.  Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. , 1993, The Journal of infectious diseases.

[62]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[63]  L. Huang,et al.  Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen. , 1992, Biochimica et biophysica acta.

[64]  C. Tilcock,et al.  Polymer-derivatized technetium 99mTc-labeled liposomal blood pool agents for nuclear medicine applications. , 1993, Biochimica et biophysica acta.

[65]  E. Mayhew,et al.  Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes , 1993, Cancer.

[66]  S. Kennel,et al.  Lipid composition is important for highly efficient target binding and retention of immunoliposomes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Y. Barenholz,et al.  Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[68]  M. T. ten Kate,et al.  Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue. , 1995, The Journal of infectious diseases.

[69]  G. Hahn,et al.  Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy. , 1994, International journal of radiation oncology, biology, physics.

[70]  D. Lasič.  Sterically Stabilized Vesicles , 1994 .

[71]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[72]  J. Philippot,et al.  Liposomes as Tools in Basic Research and Industry , 1994 .

[73]  P. Couvreur,et al.  In vitro evaluation of nanoparticle formulations containing gangliosides. , 1994, Journal of drug targeting.

[74]  M. Woodle,et al.  New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. , 1994, Bioconjugate chemistry.

[75]  N. Oku,et al.  Tumor imaging with technetium-99m-DTPA encapsulated in RES-avoiding liposomes. , 1993, Nuclear medicine and biology.

[76]  M. Woodle,et al.  Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes , 1993, International journal of cancer.

[77]  A. Gabizon.  Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.

[78]  M. Bally,et al.  Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. , 1990, Biochimica et biophysica acta.

[79]  V. Torchilin,et al.  Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo , 1991, FEBS letters.

[80]  M. Yokoyama.  Block copolymers as drug carriers. , 1992, Critical reviews in therapeutic drug carrier systems.

[81]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[82]  N. Oku,et al.  Therapeutic effect of adriamycin encapsulated in long‐circulating liposomes on meth‐a‐sarcoma‐bearing mice , 1994, International journal of cancer.

[83]  M S Newman,et al.  Long circulating, cationic liposomes containing amino‐PEG‐phosphatidylethanolamine , 1994, FEBS letters.

[84]  G. Storm,et al.  Antibody-Targeted Liposomes to Deliver Doxorubicin to Ovarian Cancer Cells , 1994 .

[85]  D. Crommelin,et al.  A new application for liposomes in cancer therapy , 1993, FEBS letters.

[86]  M. Findeis,et al.  Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor. , 1994, Bioconjugate chemistry.

[87]  V. Torchilin,et al.  Chemically optimized antimyosin Fab conjugates with chelating polymers: importance of the nature of the protein-polymer single site covalent bond for biodistribution and infarction localization. , 1993, Bioconjugate chemistry.